Inclusions per participating centre.

(PDF)

Volltext
Verfasser: Anadeijda J. E. M. C. Landman (12029735)
Marjon A. de Boer (6655523)
Laura Visser (7137092)
Tobias A. J. Nijman (12029738)
Marieke A. C. Hemels (12029741)
Christiana N. Naaktgeboren (12029744)
Marijke C. van der Weide (12029747)
Ben W. Mol (8630175)
Judith O. E. H. van Laar (3927344)
Dimitri N. M. Papatsonis (12029750)
Mireille N. Bekker (11091895)
Joris van Drongelen (658270)
Mariëlle G. van Pampus (12029753)
Marieke Sueters (4231279)
David P. van der Ham (12029756)
J. Marko Sikkema (12029759)
Joost J. Zwart (12029762)
Anjoke J. M. Huisjes (12029765)
Marloes E. van Huizen (12029768)
Gunilla Kleiverda (12029771)
Janine Boon (12029774)
Maureen T. M. Franssen (12029777)
Wietske Hermes (12029780)
Harry Visser (846649)
Christianne J. M. de Groot (12029783)
Martijn A. Oudijk (12029786)
Dokumenttyp: Text
Erscheinungsdatum: 2022
Schlagwörter: Medicine / Cell Biology / Neuroscience / Pharmacology / Biotechnology / Developmental Biology / Cancer / Mental Health / Infectious Diseases / white ethnic origin / serious adverse events / possible beneficial effect / culture proven sepsis / additional preventive measures / spontaneous preterm birth / preterm birth occurred / mean age 32 / main study limitation / april study ): / perinatal death ) / secondary outcomes included / poor neonatal outcome / dutch trial register / april study ) / 37 weeks occurred / preterm birth rate / dose aspirin compared / 2 %) women / 8 %) women / preterm birth / 32 ) / 37 weeks / primary outcome / neonatal morbidity / dose aspirin / 29 ) / versus 2 / grade 2 / 36 weeks / 16 weeks / 4 %) / included women / 406 women / 387 women / 194 women / ≥ 80 / xlink \ / > / treatment allocation / significantly reduce / relative risk
Sprache: unknown
Permalink: https://search.fid-benelux.de/Record/base-29019387
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://doi.org/10.1371/journal.pmed.1003892.s002